Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1996 1
1998 1
2002 1
2004 1
2009 1
2010 1
2014 1
2015 1
2021 1
2022 1
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Cervical Neuroendocrine Tumor G1"
Page 1
Persistent mutation burden drives sustained anti-tumor immune responses.
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V. Niknafs N, et al. Nat Med. 2023 Feb;29(2):440-449. doi: 10.1038/s41591-022-02163-w. Epub 2023 Jan 26. Nat Med. 2023. PMID: 36702947 Free PMC article.
Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed to consistently demonstrate clinical utility in predicting responses in the context of immunotherapy. ...Persistent mutations were retained in the context of tumor …
Tumor mutation burden is an imperfect proxy of tumor foreignness and has therefore failed to consistently demonstrate clinical …
Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial.
Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen DT, Berglund A, Michael L, Aoki M, Wang MH, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-Segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Kim S, et al. Lancet. 2022 Sep 24;400(10357):1008-1019. doi: 10.1016/S0140-6736(22)01659-2. Epub 2022 Sep 12. Lancet. 2022. PMID: 36108657 Free PMC article. Clinical Trial.
Of the patients who had previously had ICI exposure, eight (31%) of 26 patients (95% CI 15-52) had an objective response and four (15% [5-36]) had a complete response. No significant differences in ORR were observed between groups A (18 [72%] of 25 patients) and B (12 [52% …
Of the patients who had previously had ICI exposure, eight (31%) of 26 patients (95% CI 15-52) had an objective response and four (15% [5-36 …
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Khushalani NI, Ott PA, Ferris RL, Cascone T, Schadendorf D, Le DT, Sharma MR, Barlesi F, Sharfman W, Luke JJ, Melero I, Lathers D, Neely J, Suryawanshi S, Sanyal A, Holloway JL, Suryawanshi R, Ely S, Segal NH. Khushalani NI, et al. J Immunother Cancer. 2024 Mar 7;12(3):e007364. doi: 10.1136/jitc-2023-007364. J Immunother Cancer. 2024. PMID: 38458639 Free PMC article. Clinical Trial.
Here, we report two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tumors. METHODS: CA186-018: Patients with metastatic colorectal cancer or metastatic squamous cell carcinoma of the head and neck ( …
Here, we report two studies that evaluated urelumab in combination with cetuximab or nivolumab in patients with select, advanced solid tu …
Clear cell neuroendocrine tumor in the gallbladder diagnosed as a benign polyp preoperatively: a case report.
Sumiya R, Shimizu A, Nagai T, Ono H, Kumazawa K, Endo D, Oide T, Aoyanagi N. Sumiya R, et al. World J Surg Oncol. 2021 Jan 2;19(1):3. doi: 10.1186/s12957-020-02104-2. World J Surg Oncol. 2021. PMID: 33388069 Free PMC article.
BACKGROUND: Gallbladder neuroendocrine neoplasm is a rare disease that is divided into neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). ...Immunohistochemical staining with synaptophysin, chromogranin A, and CD56 was confined to the …
BACKGROUND: Gallbladder neuroendocrine neoplasm is a rare disease that is divided into neuroendocrine tumors (NETs) and …
Familial head and neck cancer: molecular analysis of a new clinical entity.
Yu KK, Zanation AM, Moss JR, Yarbrough WG. Yu KK, et al. Laryngoscope. 2002 Sep;112(9):1587-93. doi: 10.1097/00005537-200209000-00010. Laryngoscope. 2002. PMID: 12352668
OBJECTIVE: The tumor suppressor gene p16 encodes a cyclin-dependent kinase inhibitor that normally inhibits cell proliferation by causing a G1 cell cycle arrest. ...We identified a family with a high incidence of head and neck squamous cell carcinoma (HNSCC) …
OBJECTIVE: The tumor suppressor gene p16 encodes a cyclin-dependent kinase inhibitor that normally inhibits cell proliferation by cau …
Successful endoscopic resection for well-differentiated neuroendocrine tumor, Grade 1, in the hypopharynx.
Nakamura N, Sakagami T, Suzuki K, Takahashi Y, Noda Y, Tsuta K, Naganuma M. Nakamura N, et al. Clin J Gastroenterol. 2024 Feb;17(1):80-83. doi: 10.1007/s12328-023-01877-9. Epub 2023 Nov 2. Clin J Gastroenterol. 2024. PMID: 37919638
Well-differentiated neuroendocrine tumor, Grade 1 (NET, G1), in the hypopharynx is extremely rare. ...Histologic examination revealed well-differentiated neuroendocrine tumor, Grade 1. This case was an extremely rare and valuable case in which e …
Well-differentiated neuroendocrine tumor, Grade 1 (NET, G1), in the hypopharynx is extremely rare. ...Histologic examin …
Radio hyperthermia for re-treatment of superficial tumours.
Gabriele P, Ferrara T, Baiotto B, Garibaldi E, Marini PG, Penduzzu G, Giovannini V, Bardati F, Guiot C. Gabriele P, et al. Int J Hyperthermia. 2009 May;25(3):189-98. doi: 10.1080/02656730802669593. Int J Hyperthermia. 2009. PMID: 19212860 Free article.
The total mean retreatment dose was 31.8 Gy (20-60 Gy), while the mean of HT sessions was 5 (1 to 8), temperature ranged from 38.5 degrees C (T min) to 44 degrees C (T max). RESULTS: Acute cutaneous toxicity was 77.6% G1, 22.4% G2, none for G3. Forty-five days later we …
The total mean retreatment dose was 31.8 Gy (20-60 Gy), while the mean of HT sessions was 5 (1 to 8), temperature ranged from 38.5 degrees C …
A gelonin-containing immunotoxin directed against human breast carcinoma.
Rosenblum MG, Zuckerman JE, Marks JW, Rotbein J, Allen WR. Rosenblum MG, et al. Mol Biother. 1992 Sep;4(3):122-9. Mol Biother. 1992. PMID: 1445665
Toxins may be specifically directed to tumor cells and the toxins' potency greatly increased by covalent conjugation to monoclonal antibodies recognizing tumor-associated antigens. ...However, the immunotoxin was preferentially toxic to antigen-positive ME-180 cells …
Toxins may be specifically directed to tumor cells and the toxins' potency greatly increased by covalent conjugation to monoclonal an …
Atypical apoptosis in L929 cells induced by evodiamine isolated from Evodia rutaecarpa.
Zhang Y, Zhang QH, Wu LJ, Tashiro S, Onodera S, Ikejima T. Zhang Y, et al. J Asian Nat Prod Res. 2004 Mar;6(1):19-27. doi: 10.1080/1028602031000119772. J Asian Nat Prod Res. 2004. PMID: 14989376
Evodiamine had more potent cytotoxic effects on five tumor cell lines (human malignant melanoma A375-S2, human cervical cancer HeLa, human breast adenocarcinoma MCF7, human acute monocytic leukemia THP-1, murine fibrosarcoma L929) than rutaecarpine. ...Evodiamine in …
Evodiamine had more potent cytotoxic effects on five tumor cell lines (human malignant melanoma A375-S2, human cervical cancer …
P14ARF deficiency and its correlation with overexpression of p53/MDM2 in sporadic vestibular schwannomas.
Chen Y, Wang ZY, Wu H. Chen Y, et al. Eur Arch Otorhinolaryngol. 2015 Sep;272(9):2227-34. doi: 10.1007/s00405-014-3135-y. Epub 2014 Jun 26. Eur Arch Otorhinolaryngol. 2015. PMID: 24964769
Here, we show, by immunoblot and immunohistochemical analyses of 58 sporadic vestibular schwannomas, that upregulation of p53 was observed in 90 % of tumors examined. No p53 mutations were found in 12 % tumors analyzed. Expression of p14ARF was negative in 95 …
Here, we show, by immunoblot and immunohistochemical analyses of 58 sporadic vestibular schwannomas, that upregulation of p53 was observe …
13 results